TY - JOUR
T1 - Prednisolone, cytosine arabinoside, lomustine (CCNU), etoposide and thioguanine (PACET) combination chemotherapy for relapsed or refractory non-Hodgkin lymphoma
AU - Sweetenham, John W.
AU - McKendrick, J. J.
AU - Mead, Graham M.
AU - Whitehouse, J. Michael A.
N1 - Funding Information:
Acknowledgements-TheW essexM edicalO ncologyU nit is supported by the CancerR esearchC ampaign.D r Sweetenhamis supportedb y a grantf rom the LeukaemiaR esearchF und. We extendo ur thankst o Dr P. Smartta ndM rs S. Baileyf or theira ssistancwe ith thed atac ollection, andt o Mrs C. Pickettf or preparingth em anuscript.
PY - 1993
Y1 - 1993
N2 - 27 patients with relapsed/refractory non-Hodgkin lymphoma (NHL) received combination chemotherapy with prednisolone, cytosine arabinoside, lomustine (CCNU), etoposide and thioguanine (PACET). 25 patients are evaluable for response. 7 (26%) obtained a complete response and one (4%) a partial response. The median survival for the entire group was 6 months. 2 patients are currently alive without disease, 1 of whom has received further therapy. The regimen was intensely myelosuppressive, but was well tolerated. The complete response rate and median survival figures are comparable to previous studies of salvage therapy confirming the poor prognosis for relapsed NHL and emphasising the need for prospective randomised studies.
AB - 27 patients with relapsed/refractory non-Hodgkin lymphoma (NHL) received combination chemotherapy with prednisolone, cytosine arabinoside, lomustine (CCNU), etoposide and thioguanine (PACET). 25 patients are evaluable for response. 7 (26%) obtained a complete response and one (4%) a partial response. The median survival for the entire group was 6 months. 2 patients are currently alive without disease, 1 of whom has received further therapy. The regimen was intensely myelosuppressive, but was well tolerated. The complete response rate and median survival figures are comparable to previous studies of salvage therapy confirming the poor prognosis for relapsed NHL and emphasising the need for prospective randomised studies.
UR - http://www.scopus.com/inward/record.url?scp=0027201256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027201256&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(93)90171-B
DO - 10.1016/0959-8049(93)90171-B
M3 - Article
C2 - 8422281
AN - SCOPUS:0027201256
SN - 0959-8049
VL - 29
SP - 190
EP - 192
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 2
ER -